Nestlé agreed to divest its mainstream Vitamins, Minerals and Supplements business alongside its Holistic Health portfolio to an undisclosed private equity buyer for $1 billion in cash. The transaction removes a mid-margin segment that has traded sideways while the company's prescription nutrition and medical nutrition divisions compound at double-digit rates.

The divested assets include over-the-counter supplement brands spanning multivitamins and wellness categories that Nestlé accumulated through acquisitions over the past decade. The company will retain its Nestlé Health Science prescription nutrition arm, which serves clinical populations through enteral feeding systems and metabolic disorder treatments. The $1 billion price represents roughly 1.2x trailing revenue for the divested units, a clean exit multiple in a category where Amazon's private-label expansion has compressed branded pricing power by 18-22% since 2019.

This is the continuation of work that began when Mark Schneider took the CEO role in 2017. Nestlé has now shed $12 billion in non-core assets including U.S. confectionery, Gerber Life Insurance, and regional water brands. Each divestiture has improved the company's EBITDA margin by 60-80 basis points within eighteen months as capital reallocates to coffee systems, pet nutrition, and clinical health science. The private equity buyer gains immediate distribution through retail pharmacy and e-commerce channels, but inherits margin pressure from ingredient cost inflation and retailer consolidation that has reduced shelf negotiating power.

The $1 billion in proceeds will likely flow toward either debt reduction or acquisitions in prescription nutrition, where Nestlé has been assembling assets around rare metabolic disorders and pediatric allergy management. The company spent $2.1 billion acquiring Aimmune Therapeutics in 2020 for its peanut allergy treatment, signaling a preference for regulated, high-barrier categories over consumer wellness. Private equity ownership typically accelerates cost structure work and prepares assets for a strategic sale within 36-48 months, meaning this vitamins business will likely re-emerge under a challenger brand umbrella or fold into a larger consumer health rollup.

Allocators should monitor Nestlé's next acquisition in the $500 million to $1.5 billion range, which will clarify whether the company is building a prescription platform or simply tightening the portfolio. The private equity buyer's identity, when disclosed, will indicate whether this is a financial engineering play or a strategic platform build. If the buyer is a healthcare-focused firm rather than a consumer PE shop, expect bolt-on acquisitions in functional medicine and personalized nutrition within six months.

Nestlé's portfolio now looks more like a healthcare conglomerate than a food company, with 38% of revenue derived from categories requiring clinical validation or prescription authorization.